Besides the possible genetic reason, so far, obvious reason is few, but similar results were reported in some trials or meta-analyses of type 2 diabetes patients who were treated with SUs, AGIs, or metformin, DPP-4 inhibitors, GLP-1 receptor agonists.In SU treated patients, a subgroup analysis from the ADVANCE study indicated that [2], the mean HbA1c reduction between the group of baseline BMI <28 and baseline BMI ≥28 suggested no significant difference. Here, GLP1R is linked to type 2 diabetes mellitus.